The EU Commission announces interim measures to avert possibly irreversible consequences of a merger between two pharmaceutical companies (Illumina / GRAIL)

KEYWORDS
Reference

EU Commission, Illumina / GRAIL, Press release, 29 October 2021

Less than a month ago, the European Commission (the Commission) announced that it would open an investigation to determine whether Illumina’s decision to acquire Grail pending its review of that transaction under Regulation 139/2004 on the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
    Belgium 36 contributions 19951 visits
  • Van Bael & Bellis (Brussels)
    Belgium 141 contributions 49012 visits
  • Van Bael & Bellis (Brussels)
    Belgium 45 contributions 22879 visits
  • Van Bael & Bellis (Brussels)
    Belgium 44 contributions 21979 visits

Quotation

Michael Clancy, Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The EU Commission announces interim measures to avert possibly irreversible consequences of a merger between two pharmaceutical companies (Illumina / GRAIL), 29 October 2021, e-Competitions Interim measures, Art. N° 103345

Visites 487

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues